PMHNP Scope of Practice for Weight Loss/GLP-1 in California

If you’re a psychiatrist or psychiatric prescriber wondering whether you can legally prescribe GLP-1 agonists, phentermine, or other weight-loss medications through telehealth—and what hoops you need to jump through—you’re not alone. The explosion of online weight-loss programs has made this a hot topic, but the regulatory landscape is a minefield of federal DEA rules, state telehealth laws, and scope-of-practice questions.

Here’s what you actually need to know to stay compliant and avoid becoming a cautionary tale.

The Short Answer: Yes, But Not Everywhere (And Not the Same Way)

Federally, you can prescribe most weight-loss medications via telehealth right now—controlled substances included—thanks to a DEA extension that runs through December 31, 2026. This temporary rule lets you prescribe Schedule II-V controlled drugs (like phentermine for appetite suppression or stimulants for ADHD-related weight issues) to new patients without an in-person exam, as long as you conduct a proper telehealth evaluation.

But here’s the catch: state laws override federal permissions. Some states—like New York—require an in-person visit before you can prescribe any controlled substance via telehealth. Others—like Florida—allow it but with tight restrictions on certain drug schedules. And for non-controlled weight-loss drugs (GLP-1 agonists like semaglutide or tirzepatide), you’re generally clear to prescribe via telehealth nationwide, but you still need to follow state-specific obesity treatment standards.

If you’re a PMHNP or psychiatric PA, your scope-of-practice limitations add another layer of complexity—treating obesity may fall outside your training unless you’re working under explicit physician protocols.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Law: The DEA’s Telemedicine Extension (Through 2026)

The Ryan Haight Act Background

Pre-pandemic, federal law (the Ryan Haight Online Pharmacy Act of 2008) mandated an in-person medical evaluation before prescribing controlled substances via telemedicine. This was designed to prevent online ‘pill mills.’

COVID changed that. The DEA waived the in-person requirement during the public health emergency, and as of January 2026, HHS and DEA extended these flexibilities through the end of 2026 while they finalize permanent telehealth prescribing rules.

What This Means for Weight-Loss Prescribers

Right now, you can prescribe:

• Phentermine (Schedule IV appetite suppressant) via telehealth to new patients
• Stimulants for ADHD patients with comorbid obesity
• GLP-1 agonists like semaglutide (Wegovy/Ozempic) or tirzepatide—these aren’t controlled substances, so they were never restricted by the Ryan Haight Act

Requirements:

• Valid DEA registration
• Proper telehealth evaluation (live video in most states)
• State PDMP database check when required
• Documentation that meets standard-of-care requirements

The Catch: Permanent Rules Are Coming

DEA officials announced in January 2025 that they’re developing new rules, which will likely require either:

• A special telemedicine registration for prescribing certain controlled substances
• Limits like initial 30-day supplies for Schedule II drugs
• Possible restrictions (e.g., prescriber and patient must be in the same state)

Until those rules are finalized, the status quo holds—but providers should plan for a tighter regulatory environment post-2026.

State-by-State Breakdown: Where You Can (and Can’t) Prescribe

New York: The Strictest State

Bottom line: You cannot start a patient on phentermine or any controlled substance via telehealth alone in New York.

As of May 2025, New York requires at least one in-person medical evaluation before prescribing any controlled substance to a patient. Limited exceptions exist if:

• Another NY provider examined the patient in person within the last 12 months and referred them
• You’re covering for a colleague’s patient
• It’s an emergency with an existing patient (5-day supply max)

For non-controlled weight-loss drugs (GLP-1s), you’re fine to prescribe via telehealth as long as you conduct a proper video evaluation.

Practical workaround: Many telehealth companies operating in NY partner with local clinics for an initial in-person visit, then manage follow-up care remotely.

Additional NY requirements:

• Mandatory PDMP check within 24 hours before prescribing any Schedule II-IV drug
• All prescriptions must be e-prescribed (paper prescriptions only in rare exceptions)
• Psychiatric NPs can practice independently after 3,600 hours, but treating obesity may be outside their usual scope

Florida: Permissive for Psychiatry, Strict for Weight Loss

The good news: Florida explicitly allows telehealth prescribing of Schedule II controlled substances for psychiatric disorders—so you can prescribe Adderall or Vyvanse for ADHD via telemedicine.

The restriction: Florida prohibits telehealth prescribing of Schedule II drugs for non-psychiatric conditions (like weight loss). But since most weight-loss controlled substances are Schedule IV (phentermine), this isn’t usually an issue.

Florida’s obesity prescribing standards (applies to ALL prescribers):

• Patient must have BMI ≥30 (or ≥27 with comorbidities)
• Written informed consent required, outlining medication risks
• Quarterly re-evaluations mandatory (every 3 months minimum)
• Must provide Florida’s ‘Weight-Loss Consumer Bill of Rights’ to each patient
• Cannot prescribe SSRIs off-label for weight loss

PDMP: Must check Florida’s E-FORCSE database before prescribing any controlled substance to patients ≥16 years old.

Scope limitations: Psychiatric NPs in Florida still require physician supervision for prescribing (autonomous practice for psych NPs hasn’t passed yet). If you’re a PMHNP treating obesity, you’ll need a collaborating physician with appropriate expertise.

California: Telehealth-Friendly, But Watch the Corporate Practice Rules

Prescribing: California allows telehealth evaluations to meet the ‘appropriate prior examination’ requirement for prescribing—no in-person visit needed if your video assessment meets the standard of care.

Requirements:

• Telehealth consent (documented)
• CURES PDMP check before first prescription of any Schedule II-IV drug, then every 4 months for ongoing therapy
• E-prescribing mandatory

The California trap: Strict Corporate Practice of Medicine laws mean you can’t just launch a weight-loss telehealth company as a non-physician. Any medical practice must be physician-owned or structured through compliant management service organizations.

NP scope: As of January 2026, experienced NPs who meet AB 890 criteria can practice independently (3+ years experience, additional training). A Family NP could run an independent weight-loss practice; a Psychiatric NP would be on shakier ground without physician collaboration.

Local reality: Medi-Cal (California Medicaid) will stop covering GLP-1 medications for weight loss in January 2026, likely pushing more patients toward cash-pay telehealth models.

Texas: No State In-Person Requirement, But Strict Documentation

Good news: Texas has no blanket prohibition on telehealth prescribing of controlled substances. You can prescribe phentermine or psychiatric stimulants via live video.

Requirements:

• Establish a valid provider-patient relationship via synchronous audio-video
• Check the Texas PMP before prescribing controlled substances (required for opioids, benzos, barbiturates; best practice for all)
• Send a care summary to the patient’s primary care provider within 72 hours (with patient consent)

NP/PA limitations: Texas NPs and PAs must have a Prescriptive Authority Agreement with a Texas-licensed physician to prescribe anything. The agreement must explicitly include weight-loss drugs if they’ll prescribe them. NPs/PAs cannot prescribe Schedule II substances except in hospital/hospice settings.

Market opportunity: Texas has one of the highest obesity rates in the U.S., creating strong demand. However, the Attorney General has cracked down on misleading weight-loss advertising—keep your claims conservative.

Pennsylvania: Federal Rules Apply, Strong PDMP Requirements

Status: No specific state law prohibiting telehealth prescribing of controlled substances. Under the current DEA extension, you can prescribe phentermine or psychiatric meds via telehealth to new patients.

PDMP rules:

• Must check the PA PDMP before first opioid or benzodiazepine prescription
• Must check each time you prescribe opioids or benzos to existing patients
• Recommended (but not legally required) to check for other controlled substances like stimulants

NP/PA: No independent practice for NPs—they need Collaborative Agreements with physicians. The agreement must outline prescriptive authority, including any weight-loss medications.

Documentation: Pennsylvania expects telehealth documentation to meet in-person standards (thorough history, physical exam elements via video, clinical justification).

Illinois: Progressive Telehealth Laws, Full NP Practice Authority Available

Telehealth: Illinois explicitly allows provider-patient relationships to be established via telehealth, including audio-only in some cases (though video is recommended for weight-loss evaluations).

No state barriers: Illinois has no special restrictions on controlled substance prescribing via telehealth beyond federal requirements.

NP opportunity: Illinois offers Full Practice Authority (FPA) for APRNs after 4,000 clinical hours and additional training. With FPA, NPs can prescribe independently, including Schedule II-V controlled substances (with a consultation agreement for Schedule II opioids).

PDMP: Required check for each Schedule II narcotic (opioid) prescription and every 90 days for continuous opioid therapy. Not mandated for stimulants or other controlled substances, but recommended.

Market: Chicago and suburbs have high demand for telehealth weight management. Illinois Medicaid started covering prescription weight-loss medications in 2024, potentially increasing patient volume.

Scope of Practice: Can Psychiatrists Legally Treat Obesity?

For Psychiatrists (MD/DO)

Short answer: Yes. You hold an unrestricted medical license, which means you can legally treat obesity as long as you’re competent to do so.

Practical considerations:

• You’re held to the same standard of care as any physician treating obesity
• Document BMI, comorbidities, lifestyle counseling, and informed consent
• Consider drug interactions (e.g., phentermine with SSRIs, GLP-1s affecting blood sugar in patients on antipsychotics)
• Follow state-specific obesity treatment rules (like Florida’s quarterly follow-ups)

Why psychiatrists treat weight issues:

• Antipsychotic-induced weight gain is a common problem
• Binge-eating disorder falls within psychiatric scope
• ADHD medications (stimulants) have appetite-suppressing effects
• Some psychiatrists pursue additional certification in Obesity Medicine to strengthen credentials

For Psychiatric NPs and PAs

The scope-of-practice trap: Your license is in mental health, not metabolic conditions. Prescribing purely for obesity may be viewed as outside your training unless:

• You have explicit physician collaboration/delegation
• The collaborating physician has appropriate expertise (family medicine, endocrinology, obesity medicine—not just another psychiatrist)
• You’re treating obesity as a comorbidity of a psychiatric condition (e.g., weight gain from psych meds)
• You obtain additional training or certification in obesity management

State-specific rules:

• California/Texas: NPs must work under physician protocols unless they have independent practice authority (and even then, obesity treatment for a psych-certified NP is a gray area)
• Florida: Psych NPs still require physician supervision; treating obesity would need explicit protocol
• Illinois: With FPA, a psych NP could theoretically treat obesity independently, but professional liability would be a concern without additional training

Best practice: If you want to offer weight-loss services as a psychiatric prescriber, either:

1. Partner with a physician in obesity/primary care
2. Obtain additional certification (e.g., through the American Board of Obesity Medicine)
3. Limit treatment to obesity that’s clearly secondary to psychiatric conditions

The Economics: Why This Matters Beyond Compliance

Traditional patient acquisition for weight-loss services is expensive:

• SEO takes 6-12 months and consistent investment before generating meaningful leads
• Google Ads for mental health/weight loss keywords run $15-40+ per click
• Realistic cost per booked patient through paid ads: $200-400+
• Directory listings (Psychology Today, Zocdoc) charge monthly fees plus per-booking fees ($35-100+)
• DIY marketing can eventually work, but requires budget, expertise, and patience most solo providers don’t have

The platform model alternative: Services like Klarity Health use a pay-per-appointment model. Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee only when a pre-qualified patient books with you.

Value props:

• No upfront marketing spend or monthly subscriptions
• Patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

For psychiatrists expanding into weight management, this removes the risk of failed marketing campaigns while you’re still learning the obesity treatment market.

Compliance Checklist: Covering Your Ass

For All Providers

Before you prescribe:

• [ ] Verify you’re licensed in the state where the patient is located
• [ ] Conduct a proper telehealth evaluation (live video in most states)
• [ ] Document patient consent for telehealth (required in CA, IL, and recommended everywhere)
• [ ] Check the state PDMP if prescribing controlled substances
• [ ] Ensure your DEA registration covers the patient’s state

For weight-loss treatment specifically:

• [ ] Document BMI and comorbidities
• [ ] Obtain written informed consent about medication risks (required in FL, best practice everywhere)
• [ ] Provide lifestyle counseling (diet, exercise) or document referral to nutrition specialist
• [ ] Schedule appropriate follow-ups (quarterly minimum in FL, monthly initially per most guidelines)
• [ ] Send care summary to patient’s PCP (required in TX within 72 hours, best practice everywhere)

For controlled substances:

• [ ] Query PDMP before first prescription and per state requirements for refills
• [ ] Use e-prescribing (mandatory in most states for controlled substances)
• [ ] Document clinical justification for prescription
• [ ] In NY: Arrange in-person exam or verify exception applies

Red Flags That Trigger Disciplinary Action

State medical boards have disciplined telehealth weight-loss providers for:

• Prescribing based on online questionnaires alone (no real evaluation)
• Failing to check PDMP databases
• Misleading advertising (‘guaranteed weight loss,’ fake before/after photos)
• NPs/PAs prescribing outside their scope without proper physician oversight
• Inadequate follow-up or monitoring
• Corporate practice violations (non-physicians controlling clinical decisions)

The Near-Term Future: What to Expect

DEA Permanent Rules (2026-2027)

The DEA is finalizing regulations that will likely:

• Require special telemedicine registration for prescribing certain controlled substances
• Impose limits on initial supply (e.g., 30-day max for first prescription)
• Possibly mandate same-state prescribing (provider and patient both in one state)
• Allow continued telehealth prescribing for established patients with fewer restrictions

What to do now: Build compliant systems assuming tighter rules ahead. Document thoroughly, use video evaluations, and maintain clear clinical justification for every prescription.

State-Level Trends

Expect more states to:

• Adopt specific obesity treatment standards (like Florida’s)
• Require PDMP checks for all controlled substances (not just opioids)
• Clarify NP scope of practice for weight management
• Increase oversight of telehealth weight-loss companies (especially around compounded medications)

Opportunities:

• States joining Interstate Medical Licensure Compact (IMLC) and Nurse Licensure Compact (NLC) will make multi-state practice easier
• Expanded NP independent practice in states like California creates new market opportunities
• Growing acceptance of telehealth post-COVID means patients are comfortable with remote weight management

Frequently Asked Questions

Can I prescribe semaglutide (Ozempic/Wegovy) via telehealth to a new patient?

Yes, in almost every state. Semaglutide is not a controlled substance, so it’s not restricted by DEA rules. You need:

• Valid license in the patient’s state
• Proper telehealth evaluation meeting standard of care
• Documentation of BMI ≥30 (or ≥27 with comorbidities) per FDA labeling
• Informed consent about side effects (GI issues, potential thyroid concerns)
• Follow-up plan (monthly initially for dose titration)

Can I prescribe phentermine online without seeing the patient in person?

Depends on the state:

• Yes in Texas, Florida, California, Pennsylvania, Illinois (under current federal DEA extension through 2026)
• No in New York (in-person exam required for any controlled substance)
• Check state law for others—some may have restrictions

Even in states that allow it, you must conduct a thorough telehealth exam (live video), check the PDMP, and document clinical justification.

As a PMHNP, can I offer weight-loss treatment?

Carefully, and probably not independently. Your license is in psychiatric-mental health, not obesity medicine. Options:

1. Collaborate with a physician in family medicine or obesity medicine who can supervise/delegate weight-loss protocols
2. Obtain additional certification (e.g., obesity medicine training) to strengthen your credentials
3. Limit scope to treating weight issues secondary to psychiatric conditions (e.g., medication-induced weight gain, binge-eating disorder)

In states requiring NP practice to stay within training scope (most states), prescribing solely for obesity could trigger board scrutiny.

Do I need to see weight-loss patients in person periodically, or can it be 100% telehealth?

State-dependent:

• Florida: Requires re-evaluation every 3 months (can be via telehealth)
• Virginia: Requires in-person exam within 30 days of starting therapy, then periodic in-person follow-ups
• Most states: No specific mandate, but standard of care suggests periodic in-person visits for long-term weight management (or at minimum, annual labs and vital signs)

Best practice: Even for 100% telehealth patients, coordinate with their local PCP for annual physical exams and lab work.

What happens when the DEA extension expires in 2026?

The DEA will likely implement new permanent rules. Possible scenarios:

• Special registration required to prescribe controlled substances via telehealth (similar to DATA 2000 waiver for buprenorphine, now eliminated)
• Initial supply limits (e.g., 30-day prescription, then patient must see you in person or via established relationship)
• Same-state requirement (can only prescribe controlled substances via telehealth to patients in your state)

Action item: Monitor DEA announcements in late 2026. Plan for potential need to bring some patients in-person or adjust your model.

Can I use compounded semaglutide for weight loss?

Legally, yes—if you have a valid prescription rationale. Practically, be very careful:

• FDA has raised safety concerns about compounded GLP-1s from telehealth clinics
• Over half of primary care doctors in a 2025 survey expressed concerns about compounded medications from online prescribers
• Insurance doesn’t cover compounded versions
• Pharmacy quality varies significantly (some don’t follow USP standards)

If you prescribe compounded semaglutide, document:

• Why branded version isn’t appropriate (usually cost)
• Source pharmacy credentials (503A or 503B license)
• Patient informed consent about compounded vs. FDA-approved product

Final Thoughts: Building a Compliant, Sustainable Practice

The telehealth weight-loss market is booming, but it’s also under intense regulatory scrutiny. Primary care physicians are skeptical of online GLP-1 prescribers, state medical boards are watching for ‘pill mill’ behavior, and federal rules are in flux.

If you’re a psychiatrist, you have the prescriptive authority to treat obesity, but you need to follow the same standards as any physician in that space—thorough evaluations, lifestyle counseling, appropriate monitoring, and coordination with primary care.

If you’re a psychiatric prescriber (NP or PA), tread carefully. Treating obesity may be outside your scope unless you have explicit physician collaboration and additional training. The last thing you want is a board complaint alleging you practiced outside your scope.

The smart play:

1. Master your state’s specific rules (don’t assume what works in California applies in New York)
2. Document like you’re expecting an audit (because state boards increasingly review telehealth records)
3. Build relationships with primary care (send care summaries, coordinate labs, don’t practice in a silo)
4. Use platforms that handle compliance infrastructure (HIPAA-compliant video, e-prescribing, PDMP integration)
5. Stay current on federal rule changes (especially DEA’s permanent telehealth regulations expected in 2026-2027)

The opportunity is real—obesity affects over 40% of U.S. adults, GLP-1 demand is exploding, and telehealth removes geographic barriers. Just make sure you’re building a practice that will survive the next regulatory shift.

Sources and References

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated